These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 15007087

  • 1. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH.
    J Clin Oncol; 2004 Apr 15; 22(8):1398-403. PubMed ID: 15007087
    [Abstract] [Full Text] [Related]

  • 2. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
    Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE, Pediatric Oncology Group, Children's Cancer Group Phase II Study 9457, Children's Oncology Group.
    J Clin Oncol; 2006 Jan 01; 24(1):152-9. PubMed ID: 16382125
    [Abstract] [Full Text] [Related]

  • 3. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R.
    J Clin Oncol; 2004 Oct 15; 22(20):4119-26. PubMed ID: 15483021
    [Abstract] [Full Text] [Related]

  • 4. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2007 Feb 01; 25(4):362-9. PubMed ID: 17264331
    [Abstract] [Full Text] [Related]

  • 5. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS, Lyden E, Breneman J, Wiener E, Teot L, Meza J, Crist W, Vietti T.
    J Clin Oncol; 2001 Jan 01; 19(1):213-9. PubMed ID: 11134215
    [Abstract] [Full Text] [Related]

  • 6. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH.
    J Clin Oncol; 2009 Nov 01; 27(31):5182-8. PubMed ID: 19770373
    [Abstract] [Full Text] [Related]

  • 7. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3844-51. PubMed ID: 16921036
    [Abstract] [Full Text] [Related]

  • 8. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
    Seibel NL, Krailo M, Chen Z, Healey J, Breitfeld PP, Drachtman R, Greffe B, Nachman J, Nadel H, Sato JK, Meyers PA, Reaman GH.
    Cancer; 2007 Apr 15; 109(8):1646-53. PubMed ID: 17334983
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group.
    Raney RB, Gehan EA, Maurer HM, Newton WA, Ragab AH, Ruymann FB, Sutow WW, Tefft M.
    Cancer Clin Trials; 1979 Apr 15; 2(1):19-28. PubMed ID: 391431
    [Abstract] [Full Text] [Related]

  • 10. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
    McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C.
    Eur J Cancer; 2010 Jun 15; 46(9):1588-95. PubMed ID: 20338746
    [Abstract] [Full Text] [Related]

  • 11. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton PJ.
    Clin Cancer Res; 1999 Nov 15; 5(11):3617-31. PubMed ID: 10589779
    [Abstract] [Full Text] [Related]

  • 12. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E.
    Pediatr Hematol Oncol; 2013 Apr 15; 30(3):170-7. PubMed ID: 23484903
    [Abstract] [Full Text] [Related]

  • 13. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
    Orbach D, Rey A, Oberlin O, Sanchez de Toledo J, Terrier-Lacombe MJ, van Unnik A, Quintana E, Stevens MC.
    J Clin Oncol; 2005 Jul 01; 23(19):4363-71. PubMed ID: 15994146
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb 01; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE.
    J Clin Oncol; 2005 Jun 20; 23(18):4031-8. PubMed ID: 15767644
    [Abstract] [Full Text] [Related]

  • 16. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE.
    J Clin Oncol; 2004 Jul 15; 22(14):2873-6. PubMed ID: 15254055
    [Abstract] [Full Text] [Related]

  • 17. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.
    Pediatr Blood Cancer; 2006 Nov 15; 47(6):795-800. PubMed ID: 16411206
    [Abstract] [Full Text] [Related]

  • 18. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, Link MP.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [Abstract] [Full Text] [Related]

  • 19. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y.
    Cancer Chemother Pharmacol; 2012 Sep 15; 70(3):391-7. PubMed ID: 22806306
    [Abstract] [Full Text] [Related]

  • 20. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR.
    Pediatr Blood Cancer; 2008 Jan 15; 50(1):33-6. PubMed ID: 17091486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.